Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGO: Dulaglutide Dose Titration in T2DM
NCT00630825Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2008
- Primary completion
- Jan 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Apr 2008; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00630825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00630825.